Cover Image
市場調查報告書

歐洲的流感疫苗市場 ∼2021年:市場規模及已接種者數的預測、品牌分析

Europe Influenza Vaccines Market, Persons Vaccinated, Brand Analysis and Forecast to 2021

出版商 iGate Research Pvt Ltd 商品編碼 406616
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
歐洲的流感疫苗市場 ∼2021年:市場規模及已接種者數的預測、品牌分析 Europe Influenza Vaccines Market, Persons Vaccinated, Brand Analysis and Forecast to 2021
出版日期: 2016年12月05日 內容資訊: 英文 110 Pages
簡介

歐洲的流感疫苗的市場,預計2021年達到近6億5000萬美元的規模。新興市場上低的接種率和免疫化的政府輔助,對於疾病預防的疫苗接種重要性的認識度提高等要素促進該市場的成長。

本報告提供歐洲的流感疫苗的市場調查,歐洲整體及主要國家的已接種者數及市場規模的變化與預測,領導品牌的銷售情況與預測,市場成長的推動因素及課題分析等彙整資料。

第1章 摘要整理

第2章 歐洲市場分析、預測

  • 市場規模的變化與預測
  • 已接種者數的變化與預測

第3章 市場佔有率分析、預測

第4章 市場規模、已接種者數的變化與預測:各國

  • 德國
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 法國
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 義大利
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 西班牙
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 英國
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 荷蘭
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 愛爾蘭
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 丹麥
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 盧森堡
    • 已接種者數的變化與預測
    • 市場規模的變化與預測
  • 瑞典
    • 已接種者數的變化與預測
    • 市場規模的變化與預測

第5章 領導品牌的銷售情況與預測

  • Fluarix / FluLaval
  • Fluzone
  • Fluvirin/Flucelvax
  • Influvac (Abbott)
  • Afluria/Fluvax
  • FluMist/Fluenz
  • Flublok

第6章 主要交易

  • M&A
  • 授權協定

第7章 市場促進因素

  • 疫苗技術的演進
  • 疫苗:成本效率最好的疾病預防手段
  • 科學性、技術性突破
  • 對有效的傳播策略的持續焦點
  • 對季節性流感和疫苗接種的意識擴大

第8章 市場課題

  • 疫苗開發、核准系統的複雜性:產品開發的障礙
  • 已授權疫苗的最佳利用相關障礙
  • 對新加入經營者來說的障礙
  • 疫苗開發的類型線的縮短
  • 關於免疫化醫護人員所面臨的課題

圖表

目錄

The European influenza vaccines market is anticipated to reach nearly US$ 650 Million by 2021. Influenza is a highly communicable disease and typically has the most severe impact on children and the elderly. Influenza viruses are considered as a major cause of morbidity and mortality worldwide. The vast population base together with significantly low vaccination coverage in emerging markets, rising government support for immunization and growing awareness of the value of influenza vaccine in preventing disease are the prominent factors that will fuel the growth of the influenza vaccines market.

In the European influenza vaccines market, Germany accounts for majority of the market share. Italy is the second leading market for influenza vaccines in 2015. United Kingdom and France are the third and fourth leading market for influenza vaccines with XX% and XX% market share in 2015. Spain accounted for XX% share of the European influenza vaccines market in 2015. Netherlands, Ireland, Denmark, Luxembourg and Sweden are the other emerging market for influenza vaccines market.

In the influenza vaccines brand sales segment, Sanofi's Fluzone holds the maximum share of the market being followed by Fluvirin/Flucelvax. GSK's Fluarix/FluLaval accounts for the third highest share of the influenza vaccines market. FluMist/Fluenz and Afluria/Fluvax stands at the fourth and fifth position in the influenza vaccines market, while Flublok has captured least share of the influenza vaccines market.

iGATE Research report titled "Europe Influenza Vaccines Market, Persons Vaccinated, Brand Analysis and Forecast to 2021" provides a comprehensive analysis of the fast-evolving influenza vaccines market. This 110 Page report contains 57 Figures and 6 Tables to present a clear picture of the influenza vaccines market.

The Influenza Vaccines Market have been analyzed from 5 viewpoints:

  • 1. Europe Influenza Vaccines Market, Persons Vaccinated and Forecast (2011 - 2021)
  • 2. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2011 - 2021)
  • 3. Influenza Vaccines Brand Sales and Forecast to 2021
  • 4. Influenza Vaccines Market - Major Deals
  • 5. Influenza Vaccines Market - Driving Factors and Challenges

Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution

  • 1. Germany
  • 2. France
  • 3. Italy
  • 4. Spain
  • 5. United Kingdom
  • 6. Netherlands
  • 7. Ireland
  • 8. Denmark
  • 9. Luxembourg
  • 10. Sweden

Influenza Vaccines Brand Sales and Forecast - 7 Brands Analyzed

  • 1. Fluarix/FluLaval
  • 2. Fluzone
  • 3. Fluvirin/Flucelvax
  • 4. Influvac
  • 5. Afluria/Fluvax
  • 6. FluMist/Fluenz
  • 7. Flublok

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases

Table of Contents

1. Executive Summary

2. Europe - Influenza Vaccines Market Analysis and Forecast (2011 - 2020)

  • 2.1 Europe - Influenza Vaccines Market and Forecast (2011 - 2021)
  • 2.2 Europe - Number of Persons Vaccinated with Influenza Vaccines and Forecast (2011 - 2021)

3. Europe - Influenza Vaccines Market Share Analysis and Forecast (2011 - 2021)

4. Influenza Vaccines Market, Persons Vaccinated and Forecast - Country Wise Distribution (2011 - 2021)

  • 4.1 Germany - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.1.1 Germany - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.1.2 Germany - Influenza Vaccines Market and Forecast
  • 4.2 France - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.2.1 France - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.2.2 France - Influenza Vaccines Market and Forecast
  • 4.3 Italy - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.3.1 Italy - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.3.2 Italy - Influenza Vaccines Market and Forecast
  • 4.4 Spain - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.4.1 Spain - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.4.2 Spain - Influenza Vaccines Market and Forecast
  • 4.5 United Kingdom - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.5.1 United Kingdom - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.5.2 United Kingdom - Influenza Vaccines Market and Forecast
  • 4.6 Netherlands - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.6.1 Netherlands - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.6.2 Netherlands - Influenza Vaccines Market and Forecast
  • 4.7 Ireland - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.7.1 Ireland - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.7.2 Ireland - Influenza Vaccines Market and Forecast
  • 4.8 Denmark - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.8.1 Denmark - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.8.2 Denmark - Influenza Vaccines Market and Forecast
  • 4.9 Luxembourg - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.9.1 Luxembourg - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.9.2 Luxembourg - Influenza Vaccines Market and Forecast
  • 4.10 Sweden - Influenza Vaccines Market, Persons Vaccinated and Forecast
    • 4.10.1 Sweden - Number of Persons Vaccinated with Influenza Vaccines and Forecast
    • 4.10.2 Sweden - Influenza Vaccines Market and Forecast

5. Influenza Vaccines Brand Sales and Forecast

  • 5.1 Fluarix / FluLaval Sales and Forecast (2007 - 2021)
  • 5.2 Fluzone Sales and Forecast (2009 - 2021)
  • 5.3 Fluvirin/Flucelvax Sales and Forecast (2010 - 2021)
  • 5.4 Influvac (Acquired by Abbott) Sales (2007 - 2009)
  • 5.5 Afluria/Fluvax Sales and Forecast (2010 - 2021)
  • 5.6 FluMist/Fluenz Sales and Forecast (2007 - 2021)
  • 5.7 Flublok Sales and Forecast (2013 - 2021)

6. Influenza Vaccines Market - Major Deals

  • 6.1 Mergers and Acquisitions
  • 6.2 Licensing Agreements

7. Influenza Vaccines Market - Driving Factors

  • 7.1 Transformation of Vaccine Technologies
  • 7.2 Vaccines most Cost Effective Means of Disease Prevention
  • 7.3 Scientific & Technological Breakthroughs
  • 7.4 Continuous Focus on Effective Communication Strategies
  • 7.5 Increasing Awareness on Seasonal Influenza & Vaccination

8. Influenza Vaccines Market - Challenges

  • 8.1 Complexity of Vaccine Development and Approval System Thwarts Product Development
    • 8.1.1 Legal Obstacles
    • 8.1.2 General Technical Barriers
    • 8.1.3 Economic Barriers
    • 8.1.4 Regulatory Barriers
  • 8.2 Hurdles to Optimal use of Licensed Vaccines
    • 8.2.1 Technical Obstacles
    • 8.2.2 Economic obstacles
    • 8.2.3 Cultural Obstacles
  • 8.3 Barriers to New Entrants in the Vaccines Market
  • 8.4 Reducing the Timeline for Vaccine Development
  • 8.5 Challenges Faced by Healthcare Workers in Immunization

List of Figures:

  • Figure 2-1: Europe - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 2-2: Europe - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 2-3: Europe - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 2-4: Europe - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-1: Germany - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-2: Germany - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-3: Germany - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-4: Germany - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-5: France - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-6: France - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-7: France - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-8: France - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-9: Italy - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-10: Italy - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-11: Italy - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-12: Italy - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-13: Spain - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-14: Spain - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-15: Spain - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-16: Spain - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-17: United Kingdom - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-18: United Kingdom - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-19: United Kingdom - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-20: United Kingdom - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-21: Netherlands - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-22: Netherlands - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-23: Netherlands - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-24: Netherlands - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-25: Ireland - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-26: Ireland - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-27: Ireland - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-28: Ireland - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-29: Denmark - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-30: Denmark - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-31: Denmark - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-32: Denmark - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-33: Luxembourg - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-34: Luxembourg - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-35: Luxembourg - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-36: Luxembourg - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 4-37: Sweden - Number of Persons Vaccinated with Influenza Vaccines (Million), 2011 - 2015
  • Figure 4-38: Sweden - Forecast for Number of Persons Vaccinated with Influenza Vaccines (Million), 2016 - 2021
  • Figure 4-39: Sweden - Influenza Vaccines Market (Million US$), 2011 - 2015
  • Figure 4-40: Sweden - Forecast for Influenza Vaccines Market (Million US$), 2016 - 2021
  • Figure 5-1: Global - Fluarix / Flulaval Influenza Vaccine Sales (Million US$), 2007 - 2015
  • Figure 5-2: Global - Forecast for Fluarix / Flulaval Influenza Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-3: Global - Fluzone Influenza Vaccine Sales (Million US$), 2009 - 2015
  • Figure 5-4: Global - Forecast for Fluzone Influenza Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-5: Global - Fluvirin/Flucelvax Influenza Vaccine Sales (Million US$), 2009 - 2015
  • Figure 5-6: Global - Forecast for Fluvirin/Flucelvax Influenza Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-7: Global - Influvac Influenza Vaccine Sales (Million US$), 2007 - 2009
  • Figure 5-8: Global - Afluria/Fluvax Influenza Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-9: Global - Forecast for Afluria/Fluvax Influenza Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-10: Global - FluMist/Fluenz Influenza Vaccine Sales (Million US$), 2007 - 2015
  • Figure 5-11: Global - Forecast for FluMist/Fluenz Influenza Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-12: Global - Flublok Influenza Vaccine Sales (Million US$), 2013 - 2015
  • Figure 5-13: Global - Forecast for Flublok Influenza Vaccine Sales (Million US$), 2016 - 2021

List of Tables:

  • Table 3-1: Country Wise - Influenza Vaccines Market Share (Percent), 2011 - 2015
  • Table 3-2: Country Wise - Forecast for Influenza Vaccines Market Share (Percent), 2016 - 2021
  • Table 6-1: Global - Mergers and Acquisitions in Influenza Vaccines Market (Million US$), 2005 - 2015
  • Table 6-2: Global - Licensing Agreement in Influenza Vaccines Market (Million US$), 2007 - 2015
  • Table 7-1: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations
  • Table 7-2: Initiatives Taken in Communication, Education, Training & Information Exchange Related to Seasonal Influenza in European Countries, 2009
Back to Top